Display options
Cite
Anichini G, Gandolfo C, Fabrizi S, et al. Seroprevalence to Measles Virus after Vaccination or Natural Infection in an Adult Population, in Italy. Vaccines (Basel). 2020;8(1)doi: 10.3390/vaccines8010066.
Anichini, G., Gandolfo, C., Fabrizi, S., Miceli, G. B., Terrosi, C., Gori Savellini, G., Prathyumnan, S., Orsi, D., Battista, G., & Cusi, M. G. (2020). Seroprevalence to Measles Virus after Vaccination or Natural Infection in an Adult Population, in Italy. Vaccines, 8(1), . https://doi.org/10.3390/vaccines8010066
Anichini, Gabriele, et al. "Seroprevalence to Measles Virus after Vaccination or Natural Infection in an Adult Population, in Italy." Vaccines vol. 8,1 (2020). doi: https://doi.org/10.3390/vaccines8010066
Anichini G, Gandolfo C, Fabrizi S, Miceli GB, Terrosi C, Gori Savellini G, Prathyumnan S, Orsi D, Battista G, Cusi MG. Seroprevalence to Measles Virus after Vaccination or Natural Infection in an Adult Population, in Italy. Vaccines (Basel). 2020 Feb 03;8(1). doi: 10.3390/vaccines8010066. PMID: 32028593; PMCID: PMC7158681.
Copy Download .nbib Format: NLM
Share it on

Vaccines (Basel). 2020 Feb 03;8(1). doi: 10.3390/vaccines8010066.

Seroprevalence to Measles Virus after Vaccination or Natural Infection in an Adult Population, in Italy.

Vaccines

Gabriele Anichini, Claudia Gandolfo, Simonetta Fabrizi, Giovan Battista Miceli, Chiara Terrosi, Gianni Gori Savellini, Shibily Prathyumnan, Daniela Orsi, Giuseppe Battista, Maria Grazia Cusi

Affiliations

  1. Department of Medical Biotechnologies, University of Siena, Santa Maria delle Scotte Hospital, V.le Bracci, 1 53100 Siena, Italy.
  2. Preventive Medicine and Health Surveillance Unit, Santa Maria delle Scotte Hospital, V.le Bracci, 1 53100 Siena, Italy.

PMID: 32028593 PMCID: PMC7158681 DOI: 10.3390/vaccines8010066

Abstract

An increase in measles cases worldwide, with outbreaks, has been registered in the last few years, despite the availability of a safe and highly efficacious vaccine. In addition to an inadequate vaccination coverage, even in high-income European countries studies proved that some vaccinated people were also found seronegative years after vaccination, thus increasing the number of people susceptible to measles infection. In this study, we evaluated the immunization status and the seroprevalence of measles antibodies among 1092 healthy adults, either vaccinated or naturally infected, in order to investigate the persistence of anti-measles IgG. Among subjects who received two doses of measles vaccine, the neutralizing antibody titer tended to decline over time. In addition, data collected from a neutralization assay performed on 110 healthy vaccinated subjects suggested an inverse correlation between neutralizing antibody titers and the time elapsed between the two vaccinations, with a significant decline in the neutralizing titer when the interval between the two doses was ≥11 years. On the basis of these results, monitoring the serological status of the population 10-12 years after vaccination could be important both to limit the number of people who are potentially susceptible to measles, despite the high efficacy of MMR vaccine, and to recommend a booster vaccine for the seronegatives.

Keywords: measles virus; neutralizing antibodies; seroprevalence; vaccine

References

  1. Viruses. 2016 Oct 12;8(10): - PubMed
  2. Vaccine. 1994 Feb;12(2):129-33 - PubMed
  3. Vaccine. 2018 Feb 1;36(6):818-826 - PubMed
  4. Nat Rev Dis Primers. 2016 Jul 14;2:16049 - PubMed
  5. Pediatrics. 2005 Dec;116(6):1287-91 - PubMed
  6. Vaccine. 2019 Mar 22;37(13):1775-1784 - PubMed
  7. Arch Pediatr Adolesc Med. 2007 Mar;161(3):294-301 - PubMed
  8. PLoS Pathog. 2012;8(8):e1002885 - PubMed
  9. J Infect Dis. 2017 Nov 15;216(8):977-980 - PubMed
  10. Vaccine. 2015 Sep 22;33(39):5057-63 - PubMed
  11. Vaccine. 2019 Aug 23;37(36):5323-5331 - PubMed
  12. Hum Vaccin Immunother. 2016 Mar 3;12(3):651-4 - PubMed
  13. PLoS Pathog. 2014 Dec 18;10(12):e1004482 - PubMed
  14. Euro Surveill. 2019 Jun;24(26): - PubMed
  15. Vaccines (Basel). 2019 Nov 28;7(4): - PubMed
  16. Pediatrics. 2001 May;107(5):1065-9 - PubMed
  17. Viruses. 2015 Feb 12;7(2):699-706 - PubMed
  18. Vaccine. 2007 Oct 23;25(43):7568-72 - PubMed
  19. Semin Pediatr Neurol. 2012 Sep;19(3):107-14 - PubMed
  20. Vaccine. 2011 May 17;29(22):3842-9 - PubMed
  21. J Infect Dis. 2008 Apr 1;197(7):950-6 - PubMed
  22. Science. 2015 May 8;348(6235):694-9 - PubMed
  23. MMWR Recomm Rep. 2013 Jun 14;62(RR-04):1-34 - PubMed
  24. J Infect Dis. 2020 Feb 18;221(5):721-728 - PubMed
  25. J Infect Dis. 2016 Apr 1;213(7):1115-23 - PubMed
  26. Viruses. 2016 Jul 28;8(8): - PubMed
  27. Euro Surveill. 2019 Apr;24(17): - PubMed
  28. J Infect Dis. 2011 Jul;204 Suppl 1:S133-48 - PubMed
  29. MMWR Morb Mortal Wkly Rep. 2019 Dec 06;68(48):1105-1111 - PubMed
  30. PLoS One. 2017 Jan 13;12(1):e0170257 - PubMed

Publication Types